May 21, 2018 / 7:13 AM / 3 months ago

BRIEF-GlaxoSmithKline Says Nucala Study Reports Long-Term Safety Data, Consistent Exacerbation Reduction, Improved Asthma Control

May 21 (Reuters) - GlaxoSmithKline PLC:

* NUCALA (MEPOLIZUMAB) STUDY REPORTS LONG-TERM SAFETY DATA, CONSISTENT EXACERBATION REDUCTION AND IMPROVED ASTHMA CONTROL

* NEW STUDY SHOWED ONE THIRD OF PATIENTS HAD NO EXACERBATIONS ON LONG-TERM TREATMENT WITH NUCALA Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below